Delivery Order 36F79718D0566-36C26024F0379
- This is a delivery order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Biogen U.S. Corporation, a pharmaceutical manufacturer, for QALSODY (TOFERSEN) - EMERGENCY PHARMACY. The $21,738.30 firm-fixed-price order was placed against Biogen's Pharmaceuticals and Drugs General Services Administration (GSA) Schedule contract, with no set-aside applied. The order will be performed in Cambridge, MA and is set to be completed by May 30, 2024. Biogen also holds a...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded a $10,869.15 delivery order to Biogen U.S. Corporation under the company's Pharmaceuticals and Drugs (FSS-61-IB) GSA Schedule contract. The firm fixed price order is for QALSODY (TOFERSEN) 6.7MG SOLN NDC: 64406-0109-01, with an anticipated completion date of April 13, 2024. Place of performance will be in Cambridge, Massachusetts. No set-aside designation was used for this order....
- The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company specializing in therapies for neurological disorders. The contract, valued at $478,860.00, is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease and multiple sclerosis. The delivery order was placed under Acorda's existing Federal Supply Schedule (FSS) contract with the VA (36F79723D0194), valued at over $16.3...
- This federal contract award is a firm fixed-price delivery order issued by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract, valued at $485,835.00, is for the supply of DALFAMPRIDINE 100 MG, a medication used to treat Parkinson's disease and multiple sclerosis symptoms. The contract was awarded on January 17, 2017, with a final completion date of...
- The Department of Veterans Affairs (VA) Veterans Health Administration and Veterans Integrated Service Network 12 awarded a firm fixed price delivery order contract to Acorda Therapeutics, Inc., a biotechnology company that develops drugs to improve therapies for neurological conditions. The $485,835.00 contract is for the delivery of DALFAMPRIDINE 10MG SA, a pharmaceutical product, with a completion date of July 14, 2017. The contract was issued off of the VA's Pharmaceuticals and Drugs Federal...
- This is a delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company that specializes in developing and commercializing therapies for neurological disorders. The contract is for the supply of Dalfampridine 10mg sustained-action (SA) tablets, a medication used to treat multiple sclerosis. The contract has a ceiling value of $485,835.00 and is a firm fixed-price delivery order, with no set-aside designation. This contract...
- This is a firm fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The $478,860.00 contract is for the provision of DALFAMPRIDINE, which is likely a pharmaceutical product used to treat Parkinson's disease or multiple sclerosis. The delivery order was issued under Acorda's existing Federal Supply Schedule (FSS) contract with the VA, valued at over $16.3 million, for the...
- This is a firm fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Acorda Therapeutics, Inc., a biotechnology company specializing in neurological therapies. The $861,948.00 contract is for the supply of DALFAMPRIDINE, a medication used to treat Parkinson's disease symptoms. The contract is placed under Acorda's Federal Supply Schedule (FSS) contract with the VA, which is valued at over $16.3 million and allows the VA to procure Acorda's pharmaceutical...
- The Department of Veterans Affairs Veterans Health Administration awarded a $652,376 delivery order to Neurocrine Biosciences, Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The order calls for the delivery of VALBENAZINE 80MG capsules to the Hines VA Medical Center in Illinois. The one-week period of performance from November 3 to November 10, 2020 indicates this was likely an urgent order to treat veterans for a condition addressed by the medication. Neurocrine...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 awarded Takeda Pharmaceuticals America Inc. a $14,483.70 firm fixed price delivery order for pharmacy products under the company's Pharmaceuticals and Drugs GSA Schedule contract number FSS-61-IB. The delivery order, which does not have a set-aside designation, is for Vonvendi to support the agency's pharmacy programs and will be completed by December 11, 2023. Takeda Pharmaceuticals...
- Pharmaceuticals and Drugs (FSS-61-IB)Master GSA Schedule
- 36F79718D0566Federal Supply Schedule
- 36F79718D0566-36C26024F0379Delivery Order
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm-fixed-price delivery order to Biogen U.S. Corporation, a pharmaceutical manufacturer, for the supply of QALSODY and QALSODY (TOFERSEN) 6.7MG SOLN. This $43,476.60 order was placed against Biogen's Pharmaceuticals and Drugs GSA Schedule contract and will be delivered by June 1, 2024. Biogen also holds a $11.39 million single-award indefinite delivery contract with the VA National Acquisition Center to provide ranibizumab vials and syringes, likely for treating eye conditions, as well as a $430,578.10 Blanket Purchase Agreement for Spinraza, a drug used to treat spinal muscular atrophy. These contract vehicles enable the VA to efficiently acquire necessary pharmaceuticals for veterans nationwide through December 2024. The contract award did not have a set-aside designation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.5k | 4/24/24 |